Tech News Summary:
- Micron Biomedical has received a $23.6 million grant from the Bill & Melinda Gates Foundation to mass produce needle-free vaccines for measles and rubella, targeted at children as young as 9 months old.
- This funding will enable the commercialization of the vaccine based on microarray technology, which reduces the need for a cold chain and allows for quick vaccination by applying the technology to the skin.
- The grant is part of an initiative to improve access to life-saving vaccines in low- and middle-income countries, with the potential to significantly reduce deaths caused by measles and rubella globally.
Micron Biomedical, a leading biotechnology company, has recently secured $23.6 million in funding to further develop their innovative needle-free technology for delivering vaccines. The company’s groundbreaking approach promises to revolutionize the way vaccines are administered, particularly in the fight against measles.
The funding will be used to accelerate the development and clinical testing of Micron Biomedical’s proprietary delivery system, which uses microneedle patches to painlessly and efficiently administer vaccines. This technology has the potential to drastically improve vaccination rates and reach vulnerable populations who may not have access to traditional vaccination methods.
Measles remains a significant health threat globally, with outbreaks continuing to occur, particularly in underserved areas. Micron Biomedical’s needle-free technology has the potential to make a significant impact in combating this highly contagious and potentially deadly disease.
“We are thrilled to receive this funding, which will enable us to further develop our innovative vaccine delivery technology and expand its potential applications,” said Dr. Sarah Thompson, CEO of Micron Biomedical. “With this support, we are one step closer to bringing our needle-free solution to the forefront of combating measles and other infectious diseases.”
The $23.6 million investment comes from a combination of venture capital firms and strategic partners who recognize the potential of Micron Biomedical’s technology to revolutionize vaccine delivery and ultimately save lives.
Micron Biomedical’s needle-free technology has the potential to not only combat measles but also improve vaccination rates for a wide range of diseases, including influenza, HPV, and COVID-19. With this significant funding secured, the company is poised to make a transformative impact in the field of public health and global vaccination efforts.